The Cystic Fibrosis Foundation has announced an investment of up to $24 million in Prime Medicine for the development of a gene editing therapy targeting cystic fibrosis. This funding will support preclinical research on the G542X mutation, which currently has no available therapies. The company is exploring gene editing technology for potential treatments. This investment builds on prior support aimed at demonstrating the versatility of prime editing.
Who to call at Prime Medicine, and when
A new round usually means Prime Medicine is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Prime Medicine raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Prime Medicine, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Prime Medicine. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Prime Medicine
Location
Cambridge, Massachusetts, United States
About
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Taken together, Prime Editing’s versatile gene editing capabilities could unlock opportunities across thousands of potential indications.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Prime Medicine raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
CambridgeBiotechnologyHealth CareGeneticsTherapeutics